Hni-Hirudin
Hirudo nipponia salivary-gland hirudin variant identified by transcriptome + in situ hybridisation — Kim 2024 and Shi 2023 (Pichia pastoris recombinant production, 14,000 ATU/mL).
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Hni-Hirudin7 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Hni-Hirudin's antithrombin activity in recombinant assays does NOT establish clinical efficacy. No FDA-approved derivative; H. nipponia is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudo nipponia
- Discovered
- 2023 · Shi P et al.; Kim JH et al.
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Shi P et al. (2023), Sci Rep · PMID 36973525
- Kim JH et al. (2024), Dev Comp Immunol · PMID 38158145
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.